This phase II trial is alternating the use of two oral drugs (Osimertinib and Gefitinib) in patients with advanced EGFR-T790M positive Non-Small Cell (NSC) Lung Cancer.
This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 2 trial to determine the efficacy, safety, and feasibility of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
Other Non-Commercial Sponsor
University of Sydney
Osimertinib 80 mg daily for 8 weeks (Induction Phase).
Gefitinib 250 mg daily for 4 weeks then osimertinib 80 mg daily for 4 weeks, and continue alternating (i.e. alternating 4 weekly cylces of each drug) until disease progression or unacceptable toxicity (Alternating Phase).
Following disease progression and if deemed appropriate by the treating Investigator, Osimertinib 80 mg daily until further progression or unacceptable toxicity (Post-Progression Phase).
Both Osimertinib and Gefitinib will be supplied as tablets for oral administration. Adherence will be monitored by counting returned empty drug packets
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More